Differentiation and tumour aggressiveness, though complementary, but both depending on aerobic glycolysis for at least a part of their cycle, we have thus uncovered a novel target in the form of ADPGK on the cross-roads of these pathways, and its targeting via development of novel therapeutics could prove to be indispensable for curbing aggressively growing malignancies. Here, ADPGK is linked to neoplasm.